Pipeline

GDC-0973 (XL518)

GDC-0973, an inhibitor of the MEK pathway, is being developed by Genentech, a member of the Roche Group under a collaboration agreement with Exelixis.

Partnered Compounds

We have established multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical companies. These partnerships are designed to advance the development of a variety of promising therapies for cancer and other serious diseases.